ABSTRACT
Interferon (IFN) is the first cytokine to be used therapeutically with antiviral, antiproliferative and immunoregulatory effects. Dermatologic Food and Drug Administration approved indications for IFNs include condyloma accuminata, AIDS-related Kaposi sarcoma, melanoma, chronic granulomatous disease. Off-label dermatologic uses are cutaneous T-cell lymphoma, basal cell carcinoma, squamous cell carcinoma, actinic keratosis, keratoacanthoma, keloid, verruca vulgaris, hemangioma and Behçet disease. IFN-α2a, α2b, β and γ are the most common forms used in skin diseases. This review will focus on mechanism of action for IFNs, antiviral, antiproliferative and immunoregulatory effects, the dermatologic indications, side effects and contraindications.
Keywords:
Dermatology, dermatooncology, interferons, treatment
References
1
Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8-32.
2
Ismail A, Yusuf N. Type I Interferons: Key Players in Normal Skin and Select Cutaneous Malignancies. Dermatol Res Pract 2014; 2014: 847545.
3
Bandurska K, Król I, Myga-Nowak M. [Interferons: between structure and function]. Postepy Hig Med Dosw (Online) 2014; 68: 428-440.
4
Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010; 30: 555-564.
5
Kaçar S, Özuğuz P. İnterferonlar. Turkiye Klinikleri J Dermatol-Special Topics 2014; 7: 71-79.
6
Jackson J, Callen J. Systemic immunomodulators. Bolognia Ed. 4th edition. London, Elsevier, 2242-2244.
7
Arnaud P. [The interferons: pharmacology, mechanism of action, tolerance and side effects]. Rev Med Interne 2002;(23 Suppl 4): 449s-458s.
8
De Andrea M, Ravera R, Gioia D, Gariglio M, Landolfo S. The interferon system: an overview. Eur J Paediatr Neurol 2002;6 Suppl A:A41-6; discussion A55-8.
9
Yang J, Pu YG, Zeng ZM, Yu ZJ, Huang N, Deng QW. Interferon for the treatment of genital warts: a systematic review. BMC Infect Dis 2009; 9: 156.
10
Krown SE. AIDS-associated Kaposi’s sarcoma: is there still a role for interferon alfa? Cytokine Growth Factor Rev 2007; 18: 395-402.
11
Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 2002; 29(3 Suppl 7): 18-26.
12
Shepherd FA, Beaulieu R, Gelmon K, et al. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi’s sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J Clin Oncol 1998; 16: 1736-1742.
13
Di Trolio R, Simeone E, Di Lorenzo G, Buonerba C, Ascierto PA. The use of interferon in melanoma patients: a systematic review. Cytokine Growth Factor Rev 2015; 26: 203-212.
14
Dimitriou F, Braun RP, Mangana J. Update on adjuvant melanoma therapy. Curr Opin Oncol 2018; 30: 118-124.
15
Ives NJ, Suciu S, Eggermont AMM, et al. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer 2017; 82: 171-183.
16
Domingues B, Lopes JM, Soares P, Pópulo H. Melanoma treatment in review. Immunotargets Ther 2018; 7: 35-49.
17
Filiz S, Uygun DF, Yeğin O. Chronic Granulomatous Disease. Turk J Immunol 2013; 1: 22-31.
18
Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol 2010; 63: 689-702.
19
López-Albaitero A, Nayak JV, Ogino T, et al. Role of antigenprocessing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006; 176: 3402-3409.
20
Hanlon A, Kim J, Leffell DJ. Intralesional interferon alfa-2b for refractory, recurrent squamous cell carcinoma of the face. J Am Acad Dermatol 2013; 69: 1070-1072.
21
Edwards L, Levine N, Smiles KA. The effect of topical interferon alpha 2b on actinic keratoses. J Dermatol Surg Oncol 1990; 16: 446-449.
22
Spaccarelli N, Rook AH. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma. Dermatol Clin 2015; 33: 731-745.
23
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol 2014; 70:223.e1-17; quiz 240-242.
24
Oh CK, Son HS, Lee JB, Jang HS, Kwon KS. Intralesional interferon alfa-2b treatment of keratoacanthomas. J Am Acad Dermatol 2004; 51(5 Suppl): S177-80.
25
Geusau A, Heinz-Peer G, Volc-Platzer B, Stingl G, Kirnbauer R. Regression of deeply infiltrating giant condyloma (Buschke-Lowenstein tumor) following long-term intralesional interferon α therapy. Arch Dermatol 2000; 136: 707-710.
26
Tian YP, Yao L, Malla P, Song Y, Li SS. Successful treatment of giant condyloma acuminatum with combination retinoid and interferon-γ therapy. Int J STD AIDS 2012; 23: 445-447.
27
Berman B. Biological agents for controlling excessive scarring. Am J Clin Dermatol 2010; 11(Suppl 1): 31-34.
28
Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns 2014; 40: 1255-1266.
29
Lee JH, Kim SE, Lee AY. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. Int J Dermatol 2008; 47: 183-186.
30
Grimal I, Duveau E, Enjolras O, Verret JL, Giniès JL. [Effectiveness and dangers of interferon-alpha in the treatment of severe hemangiomas in infants]. Arch Pediatr 2000; 7: 163-167.
31
Wechsler B, Du-Boutin LT. [Interferons and Behçet’s disease]. Rev Med Interne 2002;(23 Suppl 4): 495s-499s.
